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INTRODUCTION

• Refractory vasodilatory shock develops from uncontrolled
vasodilation and hyporesponsiveness to vasopressors.

FIGURES

• Management of calcium channel blockers (CCB) toxicity can be
difficult because it can result in refractory vasodilatory shock
making it often fatal despite standard treatment.

CASE PRESENTATION

• 21-year-old male with history of depression and prior suicide
attempts presented after intentional ingestion of amlodipine
(300 mg) and metformin (150 tablets of 1000 mg).
• Presented with slightly altered mentation and hypotension, then
quickly deteriorated and required intubation and high
vasopressor requirements.
• Transferred to PSVMC for consideration of venoarterial
extracorporeal membrane oxygenation (VA-ECMO). Since he was
hyperdynamic on echocardiogram, our team did not feel he
would benefit from VA-ECMO.
• His vasopressor requirements surpassed the normal
recommended doses
Patient

Norepinephrine

200 mcg/min

Phenylephrine

360 mcg/min

Epinephrine
Vasopressin

100 mcg/min
0.04 U/min

Normal

30 mcg/min

5-20 mcg/min

5-200 mcg min

0.01-0.04 U/min

• Due to no improvement, methylene blue and
hydroxycobalamine (vitamin B12) were initiated for his refractory
shock.
• He responded favorably to this therapy. Norepinephrine dose
was halved and Epinephrine down to 10 mcg/min almost
immediately.
• It took several days to wean him off the vasopressors and he was
able to transfer to the medical floor in stable condition.
• References upon request

Figure 1: Mechanism of methylene blue: Cytokines and ROS
upregulate nitric oxide synthase and stimulates soluble
guanylate cyclase (sGC), both of which generate cGMP. cGMP
shifts calcium into the sarcoplasmic reticulum (SR) therefore
lowering intracellular calcium concentration and decreasing
contraction. Methylene blue inhibits both NO synthesis and
cGMP synthesis

Figure 2 & 3: Methylene blue turns
urine green blue and vitamin B12 turns
urine red

DISCUSSION

• Higher doses of vasopressors are typically required for CCB toxicity and coingestions can also alter the pharmacokinetics in unpredictable ways.
• Emerging therapies, such as methylene blue and vitamin B12, were tried. These
have previously been used in cardiac patients who experienced vasoplegia
postoperatively.
• Methylene blue and vitamin B12 are thought to increase systemic vascular
resistance by decreasing nitric oxide synthesis thereby preventing smooth muscle
relaxation allowing vasoconstriction in response to catecholamines (Figure 1).
• Both therapies have been used only in case-series and case-reports; there has yet
to be randomized trials to validate their use.
• Interesting side effect of methylene blue and vitamin B12 depicted in Figure 2 & 3.
This resulted in his urine turing purple. The CRRT sensor needed to be changed so
that the machine did not think his urine was blood.
• This case highlights the importance of considering alternative therapies such as
methylene blue and vitamin B12 in cases of refractory shock unresponsive to
standard therapies.
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